GlassScriptPhysician profile
Kimberly Napier
NPI 1023691938
$4,892.64
in general payments reported to CMS, 2019-2025
11 companies · $2,325 in 2025
The $2,325 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $400 · 2023: $1,456 · 2024: $711 · 2025: $2,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,474 · Education: $18.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,474.13 |
| Education | $18.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,342.84 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $831.41 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $603.19 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $458.40 | 2024-2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $372.63 | 2023-2025 | Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $340.21 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $338.41 | 2023-2025 | Caplyta |
| Alkermes, INC. | $211.29 | 2022-2025 | Lybalvi, Aristada |
| Tms Neurohealth Centers INC. | $138.95 | 2025 | Tms Neurohealth Centers INC. |
| Luye Pharma (USA) LTD. | $133.22 | 2025 | Erzofri Extended-Release |
| Janssen Pharmaceuticals, INC | $122.09 | 2024-2025 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Napier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.